Cell and gene therapy companies raised $10.7bn during the first half of 2020, exceeding the $9.8bn full-year total that the regenerative medicine sector raised in 2019. Venture capital financings in the first half of this year totaled $3.03bn, which puts cell and gene therapy VC deals on track to beat 2019’s full-year total of $4.26bn, according to the Alliance for Regenerative Medicine’s (ARM’s) Global Regenerative Medicine and Advanced Therapy Report for the first half of 2020.
Investor exuberance for biopharmaceutical investments in general has soared in 2020, in part because new therapeutics and vaccines are essential...






